GVR Report cover Solid Tumor Testing Market Size, Share & Trends Report

Solid Tumor Testing Market Size, Share & Trends Analysis Report By Type (PCR, Genetic Testing), By Application (Prostate, Breast), By End-user, By Region, And Segment Forecasts, 2023 To 2030

  • Historical Data: ---
  • Forecast Period: 1 - 2030 
  • Industry: Healthcare

A solid tumor is described as uncontrolled cell growth that does not contain fluids or cysts. Solid tumor testing is used to diagnose malignancies in their early phases. Despite enormous efforts to investigate and develop diagnostic tests, it remains one of the top causes of death. 

There are two kinds of tumor testing: conventional testing and genetic testing. Genetic testing such as fluorescent In-Situ hybridization (FISH), real-time PCR (RT-PCR), fragment analysis, and next-generation sequencing are mostly used to provide precise information about the molecular and genetic makeup of malignancies. Diagnostic analysis of these neoplasms allows evaluating the individual patient cancer risk by performing high - throughput screening genotyping analysis of tumor DNA and predicting the reaction outcome of the therapy.

The solid tumor testing market has grown as a result of a surge in the geriatric population, a rise in the incidence of various cancers such as bladder, breast, lungs and brain cancer amongst others, and rise in demand for minimally invasive process for the diagnosis of solid tumors. In addition, industry development amongst market players are also likely to accelerate market growth during the forecast year. For instance, in March 2022, Bristol Myers Squibb announced its strategic plan to acquire Turning Point Therapeutics, a company actively operating in precision oncology. The acquisition is expected to help Bristol Myers Squibb to consolidate its position in solid tumor testing market. Moreover, in September 2022, Seagen and LAVA Therapeutics announced a strategic collaboration to develop and commercialize LAVA-1223, an advanced epidermal growth factor receptor which can efficiently detect solid tumors.

As reported by the American Cancer Society, roughly 1.9 million new cancer cases are anticipated for diagnosis in the United States in 2022, with 609,360 mortalities. Further, as per the U. S. Department of Health and Human Services, approximately 151,030 new cases of colorectal cancer will be identified in the U. S. by the end of 2022.

Solid Tumor Testing Market Segmentation 




Genetic Testing (Genetic Test Type (Next generation sequencing (NGS), Real-time PCR (RT-PCR), Fluorescent In-Situ Hybridization (FISH), Fragment Analysis); Conventional Testing.


Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, Brain, Thyroid, Liver, Ovarian, Others.

End user

Pharmaceutical and biotechnology companies; Hospitals; Contract research organizations;Academic research institutions


North America; Europe; Asia Pacific; Latin America; Middle East & Africa


Major companies operating in the solid tumor testing market include QIAGEN, QUEST DIAGNOSTICS INCORPORATED, Abbott Laboratories, Agilent Technologies Inc., Biocare Medical LLC, , F. Hoffmann-La Roche AG, ILLUMINA, INC., MedGenome Labs Private Ltd, MYRIAD GENETICS, INC., Thermo Fisher Scientific, Inc., BioLifeSolutions Inc., AMSBIO, Princeton CryoTech, STEMCELL Technologies Inc., LGC SeraCare, Corning Incorporated, and CellGenix GmbH.

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.